Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04351230
Title Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United

Her2-receptor positive breast cancer


Abemaciclib + Ado-trastuzumab emtansine

Ado-trastuzumab emtansine

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST